Drug intelligence / Profile preview

Autologous Dendritic Cell Immunotherapy (JES Kasih Nusantara Sejahtera)

Development stage: Unknown
Lead developer: JES Kasih Nusantara Sejahtera
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Subcutaneous

Overview

PT. JES Kasih Nusantara Sejahtera is developing an autologous dendritic cell-based immunotherapy for the treatment of diabetic neuropathy. This cell therapy involves the extraction of a patient's own dendritic cells, which are then processed and re-administered to modulate immune-mediated inflammatory processes associated with diabetic complications. Clinical evaluation in a Phase 1/2 trial conducted at Gatot Soebroto Army Hospital in Indonesia demonstrated improvements in the Toronto Clinical Neuropathy Score (TCNS) and modulation of inflammatory biomarkers, including Transforming growth factor beta (TGF-beta) and Vascular cell adhesion molecule 1 (VCAM-1). The therapy is part of a broader platform targeting various immune-related and infectious conditions, including COVID-19 and autoimmune diseases.

Other names: dendritic cell immunotherapy-JES Kasih Nusantara Sejahterah-cell therapy-autologous dendritic cell-Diabetic NeuropathyDendritic Cell Immunotherapy (Diabetic Neuropathy)Autologous Dendritic Cell Immunotherapy

Beyond the preview

Go deeper on Autologous Dendritic Cell Immunotherapy (JES Kasih Nusantara Sejahtera).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autologous Dendritic Cell Immunotherapy (JES Kasih Nusantara Sejahtera).

Explore the full profile